{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:16:59Z","timestamp":1772165819577,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-025-06662-1","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T22:55:27Z","timestamp":1743720927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is muscarinic receptor agonist effective and tolerant for schizophrenia?"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaonan","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongshan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbo","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"6662_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","volume":"77","author":"RA McCutcheon","year":"2020","unstructured":"McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An overview. JAMA Psychiatry. 2020;77:201\u201310.","journal-title":"JAMA Psychiatry"},{"key":"6662_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.euroneuro.2005.04.009","volume":"15","author":"W R\u00f6ssler","year":"2005","unstructured":"R\u00f6ssler W, Salize HJ, van Os J, Riecher-R\u00f6ssler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2005;15:399\u2013409.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"6662_CR3","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","volume":"148","author":"KL Davis","year":"1991","unstructured":"Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148:1474\u201386.","journal-title":"Am J Psychiatry"},{"key":"6662_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1056\/NEJMra1801490","volume":"379","author":"JA Lieberman","year":"2018","unstructured":"Lieberman JA, First MB. Psychotic disorders. N Engl J Med. 2018;379:270\u201380.","journal-title":"N Engl J Med"},{"key":"6662_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.euroneuro.2024.04.012","volume":"84","author":"O Agid","year":"2024","unstructured":"Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Howes OD, Sepp\u00e4l\u00e4 N, et al. Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: A narrative review and recommendation for clinical practice. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2024;84:35\u201347.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"6662_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","volume":"36","author":"CU Correll","year":"2022","unstructured":"Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Sepp\u00e4l\u00e4 N, et al. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-Resistant schizophrenia. CNS Drugs. 2022;36:659\u201379.","journal-title":"CNS Drugs"},{"key":"6662_CR7","doi-asserted-by":"crossref","unstructured":"Lind PA, Parker RK, Northwood K, Siskind DJ, Medland SE. Clozapine efficacy and adverse drug reactions among a nationwide study of 1021 Australians prescribed clozapine: the clozagene study. Schizophr Bull. 2024;:sbae065.","DOI":"10.31234\/osf.io\/czd9f"},{"key":"6662_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1176\/ps.2008.59.5.500","volume":"59","author":"MS Swartz","year":"2008","unstructured":"Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RSE, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv Wash DC. 2008;59:500\u20136.","journal-title":"Psychiatr Serv Wash DC"},{"key":"6662_CR9","doi-asserted-by":"publisher","first-page":"26548","DOI":"10.4088\/JCP.MS19053BR3C","volume":"81","author":"CU Correll","year":"2020","unstructured":"Correll CU. Current treatment options and emerging agents for schizophrenia. J Clin Psychiatry. 2020;81:26548.","journal-title":"J Clin Psychiatry"},{"key":"6662_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/npp.2011.199","volume":"37","author":"CK Jones","year":"2012","unstructured":"Jones CK, Byun N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2012;37:16\u201342.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"6662_CR11","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","volume":"172","author":"SJ Kaar","year":"2020","unstructured":"Kaar SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704.","journal-title":"Neuropharmacology"},{"key":"6662_CR12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/ijnp\/pyad011","volume":"26","author":"JT Kantrowitz","year":"2023","unstructured":"Kantrowitz JT, Correll CU, Jain R, Cutler AJ. New developments in the treatment of schizophrenia: an expert roundtable. Int J Neuropsychopharmacol. 2023;26:322\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"key":"6662_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11920-021-01298-w","volume":"23","author":"M Pahwa","year":"2021","unstructured":"Pahwa M, Sleem A, Elsayed OH, Good ME, El-Mallakh RS. New antipsychotic medications in the last decade. Curr Psychiatry Rep. 2021;23:87.","journal-title":"Curr Psychiatry Rep"},{"key":"6662_CR14","unstructured":"Paul P SM, Yohn SE, Brannan SK, Neugebauer NM, Breier A. Muscarinic receptor activators as novel treatments for schizophrenia. Biol Psychiatry. 2024. S0006-3223(24)01173-9."},{"key":"6662_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","volume":"179","author":"SM Paul","year":"2022","unstructured":"Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022;179:611\u201327.","journal-title":"Am J Psychiatry"},{"key":"6662_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/med.22042","author":"P Dudzik","year":"2024","unstructured":"Dudzik P, Lustyk K, Pytka K. Beyond dopamine: novel strategies for schizophrenia treatment. Med Res Rev. 2024. https:\/\/doi.org\/10.1002\/med.22042.","journal-title":"Med Res Rev"},{"key":"6662_CR17","doi-asserted-by":"publisher","first-page":"113201","DOI":"10.1016\/j.bbr.2021.113201","volume":"405","author":"DJ Foster","year":"2021","unstructured":"Foster DJ, Bryant ZK, Conn PJ. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021;405:113201.","journal-title":"Behav Brain Res"},{"key":"6662_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euroneuro.2024.11.013","volume":"92","author":"N Fabiano","year":"2025","unstructured":"Fabiano N, Wong S, Zhou C, Correll CU, H\u00f8jlund M, Solmi M. Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2025;92:62\u201373.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6662_CR19","doi-asserted-by":"publisher","first-page":"8124","DOI":"10.1073\/pnas.1508846112","volume":"112","author":"JH Shin","year":"2015","unstructured":"Shin JH, Adrover MF, Wess J, Alvarez VA. Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens. Proc Natl Acad Sci U S A. 2015;112:8124\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6662_CR20","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1523\/JNEUROSCI.5620-09.2010","volume":"30","author":"S Threlfell","year":"2010","unstructured":"Threlfell S, Clements MA, Khodai T, Pienaar IS, Exley R, Wess J, et al. Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J Neurosci Off J Soc Neurosci. 2010;30:3398\u2013408.","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"6662_CR21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","volume":"91","author":"DJ Foster","year":"2016","unstructured":"Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, et al. Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 Receptor-Dependent Inhibition of dopamine release. Neuron. 2016;91:1244\u201352.","journal-title":"Neuron"},{"key":"6662_CR22","doi-asserted-by":"publisher","first-page":"112989","DOI":"10.1016\/j.psychres.2020.112989","volume":"288","author":"B Dean","year":"2020","unstructured":"Dean B, Scarr E. Muscarinic M1 and M4 receptors: hypothesis driven drug development for schizophrenia. Psychiatry Res. 2020;288:112989.","journal-title":"Psychiatry Res"},{"key":"6662_CR23","first-page":"43","volume":"19","author":"A Singh","year":"2022","unstructured":"Singh A. Xanomeline and trospium: A potential fixed drug combination (FDC) for Schizophrenia\u2014A brief review of current data. Innov Clin Neurosci. 2022;19:43\u20137.","journal-title":"Innov Clin Neurosci"},{"key":"6662_CR24","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.tips.2019.10.007","volume":"40","author":"SP Moran","year":"2019","unstructured":"Moran SP, Maksymetz J, Conn PJ. Targeting muscarinic acetylcholine receptors for the treatment of psychiatric and neurological disorders. Trends Pharmacol Sci. 2019;40:1006\u201320.","journal-title":"Trends Pharmacol Sci"},{"key":"6662_CR25","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/s41386-020-00916-0","volume":"46","author":"C Montani","year":"2021","unstructured":"Montani C, Canella C, Schwarz AJ, Li J, Gilmour G, Galbusera A, et al. The M1\/M4 preferring muscarinic agonist Xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2021;46:1194\u2013206.","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"6662_CR26","doi-asserted-by":"publisher","first-page":"1124333","DOI":"10.3389\/fncel.2023.1124333","volume":"17","author":"B Dean","year":"2023","unstructured":"Dean B, Bakker G, Ueda HR, Tobin AB, Brown A, Kanaan RAA. A growing Understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia. Front Cell Neurosci. 2023;17:1124333.","journal-title":"Front Cell Neurosci"},{"key":"6662_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717\u201326.","journal-title":"N Engl J Med"},{"key":"6662_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet Lond Engl. 2024;403:160\u201370.","journal-title":"Lancet Lond Engl"},{"key":"6662_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dub\u00e9 S, Mallinckrodt C, et al. Selective muscarinic receptor agonist Xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165:1033\u20139.","journal-title":"Am J Psychiatry"},{"key":"6662_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","volume":"8","author":"CU Correll","year":"2022","unstructured":"Correll CU, Angelov AS, Miller AC, Weiden PJ, Brannan SK. Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophr Heidelb Ger. 2022;8:109.","journal-title":"Schizophr Heidelb Ger"},{"key":"6662_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","volume":"12","author":"C Sauder","year":"2022","unstructured":"Sauder C, Allen LA, Baker E, Miller AC, Paul SM, Brannan SK. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Transl Psychiatry. 2022;12:491.","journal-title":"Transl Psychiatry"},{"key":"6662_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jpsychires.2021.10.027","volume":"144","author":"SD Targum","year":"2021","unstructured":"Targum SD, Murphy C, Breier A, Brannan SK. Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial. J Psychiatr Res. 2021;144:241\u20136.","journal-title":"J Psychiatr Res"},{"key":"6662_CR33","doi-asserted-by":"publisher","first-page":"21m14316","DOI":"10.4088\/JCP.21m14316","volume":"83","author":"PJ Weiden","year":"2022","unstructured":"Weiden PJ, Breier A, Kavanagh S, Miller AC, Brannan SK, Paul SM. Antipsychotic efficacy of KarXT (Xanomeline-Trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study. J Clin Psychiatry. 2022;83:21m14316.","journal-title":"J Clin Psychiatry"},{"key":"6662_CR34","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","volume":"400","author":"JH Krystal","year":"2022","unstructured":"Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet Lond Engl. 2022;400:2210\u201320.","journal-title":"Lancet Lond Engl"},{"key":"6662_CR35","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18:e1003583.","journal-title":"PLoS Med"},{"key":"6662_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"6662_CR37","doi-asserted-by":"crossref","unstructured":"Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A et al. The clinical global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;:16\u201323.","DOI":"10.1034\/j.1600-0447.107.s416.5.x"},{"key":"6662_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, et al. Efficacy and safety of Xanomeline-Trospium chloride in schizophrenia: A randomized clinical trial. JAMA Psychiatry. 2024. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0785.","journal-title":"JAMA Psychiatry"},{"key":"6662_CR39","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","volume":"240","author":"A Breier","year":"2023","unstructured":"Breier A, Brannan SK, Paul SM, Miller AC. Evidence of trospium\u2019s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Psychopharmacology. 2023;240:1191\u20138.","journal-title":"Psychopharmacology"},{"key":"6662_CR40","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/pcn.12474","volume":"71","author":"H Fujino","year":"2017","unstructured":"Fujino H, Sumiyoshi C, Yasuda Y, Yamamori H, Fujimoto M, Fukunaga M, et al. Estimated cognitive decline in patients with schizophrenia: A multicenter study. Psychiatry Clin Neurosci. 2017;71:294\u2013300.","journal-title":"Psychiatry Clin Neurosci"},{"key":"6662_CR41","doi-asserted-by":"crossref","unstructured":"Baran B, Lee EE. Age-Related changes in sleep and its implications for cognitive decline in aging persons with schizophrenia: A critical review. Schizophr Bull. 2024;:sbae059.","DOI":"10.31234\/osf.io\/anb29"},{"key":"6662_CR42","doi-asserted-by":"crossref","unstructured":"Legge SE, Pardi\u00f1as AF, Woolway G, Rees E, Cardno AG, Escott-Price V et al. Genetic and phenotypic features of schizophrenia in the UK biobank. JAMA Psychiatry. 2024;:e240200.","DOI":"10.1001\/jamapsychiatry.2024.0200"},{"key":"6662_CR43","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1001\/jamapsychiatry.2024.0016","volume":"81","author":"M Lee","year":"2024","unstructured":"Lee M, Cernvall M, Borg J, Plav\u00e9n-Sigray P, Larsson C, Erhardt S, et al. Cognitive function and variability in antipsychotic Drug-Naive patients with First-Episode psychosis: A systematic review and Meta-Analysis. JAMA Psychiatry. 2024;81:468\u201376.","journal-title":"JAMA Psychiatry"},{"key":"6662_CR44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","volume":"64","author":"RSE Keefe","year":"2007","unstructured":"Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007;64:633\u201347.","journal-title":"Arch Gen Psychiatry"},{"key":"6662_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/JCP.0000000000001232","volume":"42","author":"K Ohi","year":"2022","unstructured":"Ohi K, Muto Y, Sugiyama S, Shioiri T. Safety and efficacy in randomized controlled trials of Second-Generation antipsychotics versus placebo for cognitive impairments in schizophrenia: A Meta-Analysis. J Clin Psychopharmacol. 2022;42:227\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"6662_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.neubiorev.2015.05.011","volume":"55","author":"SP Carruthers","year":"2015","unstructured":"Carruthers SP, Gurvich CT, Rossell SL. The muscarinic system, cognition and schizophrenia. Neurosci Biobehav Rev. 2015;55:393\u2013402.","journal-title":"Neurosci Biobehav Rev"},{"key":"6662_CR47","doi-asserted-by":"crossref","unstructured":"Yohn SE, Harvey PD, Brannan SK, Horan WP. The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia. Front Psychiatry. 2024;15.","DOI":"10.3389\/fpsyt.2024.1421554"},{"key":"6662_CR48","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of Xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in alzheimer disease. Arch Neurol. 1997;54:465\u201373.","journal-title":"Arch Neurol"},{"key":"6662_CR49","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20240076","author":"WP Horan","year":"2024","unstructured":"Horan WP, Sauder C, Harvey PD, Ramsay IS, Yohn SE, Keefe RSE, et al. The impact of Xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials. Am J Psychiatry. 2024. https:\/\/doi.org\/10.1176\/appi.ajp.20240076.","journal-title":"Am J Psychiatry"},{"key":"6662_CR50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","volume":"20","author":"M Halaska","year":"2003","unstructured":"Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Br\u00fchl B, H\u00f6fner K, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20:392\u20139.","journal-title":"World J Urol"},{"key":"6662_CR51","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2147\/NDT.S406371","volume":"19","author":"N Kidambi","year":"2023","unstructured":"Kidambi N, Elsayed OH, El-Mallakh RS. Xanomeline-Trospium and muscarinic involvement in schizophrenia. Neuropsychiatr Dis Treat. 2023;19:1145\u201351.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6662_CR52","doi-asserted-by":"crossref","unstructured":"Menegaz de Almeida A, Moraes Tamashiro F, Cavalcanti Souza ME, Luiz Silv\u00e9rio II, de Almeida Souza Miranda C, Barros Andrade \u00cd et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A systematic review and meta-analysis. J Psychiatr Res. 2025;181:262\u201372.","DOI":"10.1016\/j.jpsychires.2024.11.047"},{"key":"6662_CR53","doi-asserted-by":"publisher","DOI":"10.1055\/a-2506-7022","author":"T Kishi","year":"2025","unstructured":"Kishi T, Citrome L, Sakuma K, Hamanaka S, Nishii Y, Hatano M, et al. Xanomeline-Trospium for adults with schizophrenia experiencing acute psychosis: A systematic review and Meta-analysis of safety and tolerability outcomes. Pharmacopsychiatry. 2025. https:\/\/doi.org\/10.1055\/a-2506-7022.","journal-title":"Pharmacopsychiatry"},{"key":"6662_CR54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41537-024-00525-6","volume":"10","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Claxton A, Sauder C, Hassman HH, Kakar R, et al. Efficacy of Xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials. Schizophr Heidelb Ger. 2024;10:102.","journal-title":"Schizophr Heidelb Ger"},{"key":"6662_CR55","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nature17188","volume":"531","author":"DM Thal","year":"2016","unstructured":"Thal DM, Sun B, Feng D, Nawaratne V, Leach K, Felder CC, et al. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature. 2016;531:335\u201340.","journal-title":"Nature"},{"key":"6662_CR56","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41573-024-00958-9","volume":"23","author":"T Kenakin","year":"2024","unstructured":"Kenakin T. Know your molecule: Pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition. Nat Rev Drug Discov. 2024;23:626\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"6662_CR57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.neuron.2017.03.016","volume":"94","author":"DJ Foster","year":"2017","unstructured":"Foster DJ, Conn PJ. Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders. Neuron. 2017;94:431\u201346.","journal-title":"Neuron"},{"key":"6662_CR58","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1192\/bjp.2021.61","volume":"220","author":"D Siskind","year":"2022","unstructured":"Siskind D, Orr S, Sinha S, Yu O, Brijball B, Warren N, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry J Ment Sci. 2022;220:115\u201320.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"6662_CR59","doi-asserted-by":"crossref","unstructured":"Tramazzo S, Lian W, Ajnakina O, Carlson G, Bromet E, Kotov R, et al. Long-Term course of remission and recovery in psychotic disorders. Am J Psychiatry. 2024. appiajp20230189.","DOI":"10.1176\/appi.ajp.20230189"},{"key":"6662_CR60","doi-asserted-by":"publisher","first-page":"1390913","DOI":"10.3389\/fpsyt.2024.1390913","volume":"15","author":"Y Mo","year":"2024","unstructured":"Mo Y, Shi Z-M, Yang X-H, Lan X-J, Deng C-J, Huang X-B, et al. Deep transcranial magnetic stimulation for schizophrenia: a systematic review. Front Psychiatry. 2024;15:1390913.","journal-title":"Front Psychiatry"},{"key":"6662_CR61","doi-asserted-by":"publisher","first-page":"1308437","DOI":"10.3389\/fpsyt.2023.1308437","volume":"14","author":"X Wei","year":"2023","unstructured":"Wei X, Shi Z-M, Lan X-J, Qin Z-J, Mo Y, Wu H-W, et al. Transcranial alternating current stimulation for schizophrenia: a systematic review of randomized controlled studies. Front Psychiatry. 2023;14:1308437.","journal-title":"Front Psychiatry"},{"key":"6662_CR62","doi-asserted-by":"publisher","first-page":"103100","DOI":"10.1016\/j.ajp.2022.103100","volume":"73","author":"W-L Jiang","year":"2022","unstructured":"Jiang W-L, Cai D-B, Sun C-H, Yin F, Goerigk S, Brunoni AR, et al. Adjunctive tDCS for treatment-refractory auditory hallucinations in schizophrenia: A meta-analysis of randomized, double-blinded, sham-controlled studies. Asian J Psychiatry. 2022;73:103100.","journal-title":"Asian J Psychiatry"},{"key":"6662_CR63","doi-asserted-by":"publisher","first-page":"102887","DOI":"10.1016\/j.ajp.2021.102887","volume":"66","author":"C-H Sun","year":"2021","unstructured":"Sun C-H, Jiang W-L, Cai D-B, Wang Z-M, Sim K, Ungvari GS, et al. Adjunctive multi-session transcranial direct current stimulation for neurocognitive dysfunction in schizophrenia: A meta-analysis. Asian J Psychiatry. 2021;66:102887.","journal-title":"Asian J Psychiatry"},{"key":"6662_CR64","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.schres.2024.09.023","volume":"274","author":"AC Wright","year":"2024","unstructured":"Wright AC, McKenna A, Tice JA, Rind DM, Agboola F. A network meta-analysis of KarXT and commonly used Pharmacological interventions for schizophrenia. Schizophr Res. 2024;274:212\u20139.","journal-title":"Schizophr Res"},{"key":"6662_CR65","doi-asserted-by":"publisher","first-page":"117728","DOI":"10.1016\/j.bmc.2024.117728","volume":"105","author":"L Fu","year":"2024","unstructured":"Fu L, Luo Y, Niu L, Lin Y, Chen X, Zhang J, et al. M1\/M4 receptors as potential therapeutic treatments for schizophrenia: A comprehensive study. Bioorg Med Chem. 2024;105:117728.","journal-title":"Bioorg Med Chem"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06662-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T21:43:56Z","timestamp":1743803036000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06662-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6662"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06662-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5387999\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our manuscript was not applied to human beings and thus requires no ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"323"}}